Chronic neuropathic pain is a debilitating condition that remains poorly treated by current medications. Preclinical studies have indicated that cannabinoid receptor agonists have analgesic efficacy in neuropathic pain models, but this is accompanied by undesirable side effects. In recent years, novel strategies targeting the endogenous cannabinoid system have emerged, which are being mooted as safer alternatives. A recent clinical trial, however, has demonstrated that a new endocannabinoid modulator is ineffective against osteoarthritic pain, despite exhibiting efficacy during the preclinical stage. Further basic and clinical work is needed to resolve this disparity.
Cannabinoids and chronic pain
Chronic pain is a prevalent and costly health care problem (Torrance et al., ). A particularly persistent, severe and debilitating form of chronic pain is neuropathic pain. This syndrome manifests following damage or dysfunction of the peripheral nerves, spinal cord, or brain; or can be caused by stroke, multiple sclerosis or diabetes. Unfortunately, the currently recommended pharmacological treatments for neuropathic pain display poor efficacy and illicit undesirable side effects (Dworkin et al., ).
There is growing clinical evidence indicating that the cannabis constituent, Δ9-tetrahydrocannabinol (THC), and synthetic cannabinoid agonists have efficacy in chronic pain states (Lynch and Campbell, ). These human studies are based upon substantial preclinical evidence. A wide range of animal models of neuropathic pain have demonstrated that cannabinoid agonists reverse the common symptoms of neuropathic pain, including allodynia (to cool and innocuous mechanical stimuli) and hyperalgesia (to noxious thermal and mechanical stimuli) (Fox et al., ; Scott et al., ). Unfortunately, this therapeutic intervention is also associated with a number of adverse effects, including sedation and motor/cognitive impairment. Having said this, the therapeutic window between the desired and adverse effects of cannabinoids has not been systematically examined. Thus, it remains to be determined whether cannabinoids can produce pain relief at doses below the side effect threshold.
The endogenous cannabinoid system—a target for pain relief
Since exogenous cannabinoid agonists act globally throughout the central nervous system to produce their effects, isolation of the desired therapeutic action from the unwanted side effects has remained a difficult challenge. To overcome this problem, alternative approaches at targeting cannabinoid signaling have been explored (Petrosino and Di Marzo, ; Piscitelli and Di Marzo, ). Unlike exogenous cannabinoids, endogenous ligands of the cannabinoid system are synthesized in an “on demand” fashion. This suggests specific, localized release of these transmitters only in regions where their actions are pertinent. Thus, targeting endocannabinoids may provide a more effective strategy in relieving pain devoid of side effects.
Endocannabinoids are present in multiple pain-modulating regions throughout the CNS, including the periaqueductal gray (PAG), rostral ventral medulla (RVM) and spinal cord dorsal horn, where their levels are enhanced by acute nociceptive stimuli and stress (e.g., Walker et al., ; Hohmann et al., ). Interestingly, endocannabinoid levels within these regions are also enhanced in chronic pain models (Jhaveri et al., ; Petrosino et al., ; Guindon et al., ). Exogenous administration of AEA or 2-AG produces THC-like effects, but each elicits a distinct subset of the total effects observed with exogenous cannabinoid administration. Specifically, in animal models, AEA administration has been reported to produce antinociception alone (Cravatt et al., ), or evoke the full tetrad of cannabinoid agonist effects—antinociception, hypothermia, hypolocomotion and catalepsy (Smith et al., ). By contrast, 2-AG administration evokes only a subset of these effects (Lichtman et al., ). While major endocannabinoids, such as N-arachidonoyl ethanolamide (anandamide or AEA) and 2-arachidonoyl glycerol (2-AG), act via cannabinoid CB1 and CB2 receptors in a manner similar to THC and synthetic cannabinoid agonists, they may also modulate nociception via non-cannabinoid receptor targets. This is particularly the case for anandamide, which has actions on transient receptor potential vanilloid 1 (TRPV1) and peroxisome proliferator-activated receptor-α (PPAR-α), both of which are cellular targets implicated in nociception (Jhaveri et al., ; Di Marzo and De Petrocellis, ).
The actions of endocannabinoids are tightly regulated by enzymatic degradation. In particular, AEA is degraded via fatty acid amide hydrolase (FAAH), and 2-AG via monoacylglycerol lipase (MAGL) (Cravatt et al., ; Dinh et al., ). In addition, two serine hydrolases, ABHD6 and ABHD12, have recently been implicated in the hydrolysis of 2-AG (Blankman et al., ; Savinainen et al., ); however, their presence in pain pathways has yet to be confirmed. In recent years, a number of pharmacological tools have been developed which selectively inhibit FAAH and MAGL (Kathuria et al., ; Long et al., ; Ahn et al., ). Inhibition of these degradative enzymes is thought to specifically enhance endocannabinoids where they are produced on demand, resulting in more localized receptor activation compared to globally acting exogenous agonists. Considerable attention has been focused on developing degradation inhibitors to indirectly target the endocannabinoid system.
Novel endocannabinoid modulators—FAAH and MAGL inhibitors
A number of groups have demonstrated that selective FAAH inhibitors, such as URB597, OL-135, PF-3845, PF- 04457845 and ST-4070 alleviate the mechanical and cold allodynia induced in a range of animal models of chronic pain (Russo et al., ; Kinsey et al., , ; Ahn et al., ; Caprioli et al., ; Guindon et al., ). Although it has not been examined systematically, this analgesic effect occurs at doses that do not elicit the tetrad of cannabinoid-induced side effects. The evidence in support of FAAH inhibitors, however, is not unanimous. For example, our group originally found that systemic administration of URB597 had no effect on mechanical allodynia in the partial nerve ligation (PNL) model of neuropathic pain (Jayamanne et al., ), despite the synthetic analog of THC, HU-210 abolishing allodynia in the same study.
The contrasting findings between these studies might be due to a number of factors. Firstly, the above studies examined a range of different neuropathic pain models. Indeed, we have observed that, unlike the PNL model, URB597 reduces allodynia (albeit at higher doses) in the sciatic nerve chronic constriction injury (CCI) model (unpublished data). Secondly, the wide range of different FAAH inhibitor compounds administered at varying doses may account for the contrasting efficacy on allodynia, particularly since some of compounds in question did not display clear dose dependence in pain assays (e.g., Ahn et al., ). Thirdly, depending on the acute or chronic pain assay examined, it is possible that endocannabinoid activation of CB1 and TRPV1 receptors may have opposing effects on nociception, thus confounding the observed results (Maione et al., ). Together, these studies suggest that FAAH inhibitors may be efficacious for neuropathic pain, but more systematic studies need to be conducted to confirm their therapeutic potential.
Compared to FAAH inhibitors, there have been relatively fewer studies examining MAGL inhibitors in pain models. This is mainly due to their later identification and development. Nevertheless, systemic administration of the MAGL inhibitors, JZL-184 and KML-29, have been shown to alleviate allodynia in certain neuropathic pain models, without eliciting the full tetrad of cannabinoid-induced effects (Kinsey et al., , , ; Schlosburg et al., ; Guindon et al., ; Ignatowska-Jankowska et al., ). Interestingly, while analgesic efficacy is maintained during chronic administration of low doses of JZL184, tolerance has been shown to develop at higher doses (Kinsey et al., ). This latter observation is clinically relevant, since conditions like chronic pain often require long-term drug treatment.
Therapeutic potential of endocannabinoid modulators
In a recent clinical trial, the FAAH inhibitor, PF-04457845 was found ineffective in patients with osteoarthritic pain (Huggins et al., ). This was despite a clear abolition of FAAH activity and elevation in plasma AEA levels in almost all subjects tested. This finding directly contrasts those observed by the same group in an animal model of inflammatory and non-inflammatory pain, in which PF-04457845 produced a potent antinociceptive effect (Ahn et al., ). While the reason for this contrasting efficacy between humans and animals is not clear, it should be noted that the former study was likely confounded by a number of human factors (Di Marzo, ). Furthermore, the study examined only an osteoarthritic model of pain. Thus, the utility of FAAH inhibitors in the treatment of neuropathic pain remains to be explored.
Synergistic/antagonistic interactions of endocannabinoids
In chronic pain states, patients often receive drugs in combination. The aim of this approach is to produce greater or potentially synergistic analgesia at lower drug doses. Indeed, there is some clinical evidence in favour of the combined use of cannabinoid and opioid agonists in chronic pain patients, although synergy has yet to be established (Abrams et al., ).
This combinatorial approach might also be applied to the endocannabinoid modulators described above. One promising idea would be to inhibit both FAAH and MAGL (Pertwee, ). In this regard, dual inhibitors of both FAAH and MAGL have recently been developed (Long et al., ; Ramesh et al., ), although they remain to be systematically tested in chronic pain models. Because FAAH and MAGL act via distinct pathways to degrade AEA and 2-AG, dual inhibition of these degradative enzymes should boost levels of both endocannabinoids. It is unknown whether this will produce an additive or synergistic effect. Therefore, it would be interesting to observe the effect of dual FAAH/MAGL inhibition in neuropathic pain models, particularly in terms of their efficacy and therapeutic window relative to FAAH or MAGL inhibition.
It should be noted that whilst the antinociceptive effect of MAGL inhibitors is specifically abolished by CB1 receptor antagonism or knockout (Kinsey et al., , ), the effect by FAAH inhibitors is not only abolished/reduced by CB1 and CB2 receptor blockade (Russo et al., ; Kinsey et al., , ), but also antagonism of TRPV1 receptors and PPAR-α (Caprioli et al., ). Since TRPV1 and PPAR-α are predominantly pro-nociceptive targets, this suggests FAAH inhibition may produce competing, opposing actions on antinociception. Thus, it would be interesting to examine the effect of a FAAH inhibitor in combination with a TRPV1 antagonist. In this regard, the endocannabinoid-related agent, N-arachidonoyl-serotonin is a dual FAAH/TRPV1 inhibitor found to be highly effective in neuropathic pain models (De Novellis et al., ). In addition to pro-nociceptive targets, FAAH inhibition has been demonstrated to produce pro-nociceptive metabolites by diverting AEA breakdown through other metabolic pathways, such as cyclooxygenase-2 (COX-2) (Gatta et al., ). Hence, another potential interaction worth examining is dual inhibition of FAAH and COX-2. Such an approach may also lead to enhanced analgesic efficacy (Fowler et al., ).
Together, the above studies importantly highlight that while some endocannabinoid pathways act synergistically, others may act antagonistically to reduce antinociception. Therefore, prizing apart these subcellular pathways may provide a means to further improve the safety and efficacy of endocannabinoid modulators.
Future directions
While the lack of efficacy of a FAAH inhibitor in a recent clinical trial is disappointing, there are alternative approaches targeting the endocannabinoid system which may still be of promise. These need to be first addressed in animal studies before proceeding with further clinical trials. In particular, the efficacy of the highly specific, individual MAGL inhibitors and the recently developed, dual FAAH/MAGL inhibitors need to be explored in neuropathic pain models. Furthermore, the use of these degradation inhibitors in combination with agents that act on related targets should be investigated (Di Marzo, ). Both drug efficacy and side-effect profiles need to be examined systematically. This may eventually lead to an effective pharmacotherapy to treat the problematic condition of neuropathic pain.
References
1
AbramsD. I.CoueyP.ShadeS. B.KellyM. E.BenowitzN. L. (2011). Cannabinoid-opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844–851. 10.1038/clpt.2011.188
2
AhnK.SmithS. E.LiimattaM. B.BeidlerD.SadagopanN.DudleyD. T.et al. (2011). Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther. 338, 114–124. 10.1124/jpet.111.180257
3
BlankmanJ. L.SimonG. M.CravattB. F. (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14, 1347–1356. 10.1016/j.chembiol.2007.11.006
4
CaprioliA.CoccurelloR.RapinoC.Di SerioS.Di TommasoM.VertechyM.et al. (2012). The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models. J. Pharmacol. Exp. Ther. 342, 188–195. 10.1124/jpet.111.191403
5
CravattB. F.DemarestK.PatricelliM. P.BraceyM. H.GiangD. K.MartinB. R.et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 98, 9371–9376. 10.1073/pnas.161191698
6
CravattB. F.GiangD. K.MayfieldS. P.BogerD. L.LernerR. A.GilulaN. B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature384, 83–87. 10.1038/384083a0
7
De NovellisV.VitaD.GattaL.LuongoL.BelliniG.De ChiaroM.et al. (2011). The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. Mol. Pain7, 7. 10.1186/1744-8069-7-7
8
Di MarzoV. (2012). Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. Pain153, 1785–1786. 10.1016/j.pain.2012.06.016
9
Di MarzoV.De PetrocellisL. (2012). Why do cannabinoid receptors have more than one endogenous ligand?Philos. Trans. R. Soc. Lond. B. Biol. Sci. 367, 3216–3228. 10.1098/rstb.2011.0382
10
DinhT. P.CarpenterD.LeslieF. M.FreundT. F.KatonaI.SensiS. L.et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 99, 10819–10824. 10.1073/pnas.152334899
11
DworkinR. H.O'ConnorA. B.AudetteJ.BaronR.GourlayG. K.HaanpaaM. L.et al. (2010). Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc. 85, S3–14. 10.4065/mcp.2009.0649
12
FowlerC. J.NaiduP. S.LichtmanA.OnnisV. (2009). The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br. J. Pharmacol. 156, 412–419. 10.1111/j.1476-5381.2008.00029.x
13
FoxA.KesinglandA.GentryC.McNairK.PatelS.UrbanL.et al. (2001). The role of central and peripheral Cannabinoid(1) receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain92, 91–100. 10.1016/S0304-3959(00)00474-7
14
GattaL.PiscitelliF.GiordanoC.BoccellaS.LichtmanA.MaioneS.et al. (2012). Discovery of prostamide F2alpha and its role in inflammatory pain and dorsal horn nociceptive neuron hyperexcitability. PLoS ONE7:e31111. 10.1371/journal.pone.0031111
15
GuindonJ.LaiY.TakacsS. M.BradshawH. B.HohmannA. G. (2013). Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol. Res. 67, 94–109. 10.1016/j.phrs.2012.10.013
16
HohmannA. G.SuplitaR. L.BoltonN. M.NeelyM. H.FegleyD.MangieriR.et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature435, 1108–1112. 10.1038/nature03658
17
HugginsJ. P.SmartT. S.LangmanS.TaylorL.YoungT. (2012). An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain153, 1837–1846. 10.1016/j.pain.2012.04.020
18
Ignatowska-JankowskaB. M.GhoshS.CroweM. S.KinseyS. G.NiphakisM. J.AbdullahR. A.et al. (2013). In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br. J. Pharmacol. 345, 492–501. [Epub ahead of print]. 10.1111/bph.12298
19
JayamanneA.GreenwoodR.MitchellV. A.AslanS.PiomelliD.VaughanC. W. (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147, 281–288. 10.1038/sj.bjp.0706510
20
JhaveriM. D.RichardsonD.ChapmanV. (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 152, 624–632. 10.1038/sj.bjp.0707433
21
KathuriaS.GaetaniS.FegleyD.ValinoF.DurantiA.TontiniA.et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 76–81. 10.1038/nm803
22
KinseyS. G.LongJ. Z.CravattB. F.LichtmanA. H. (2010). Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J. Pain11, 1420–1428. 10.1016/j.jpain.2010.04.001
23
KinseyS. G.LongJ. Z.O'NealS. T.AbdullahR. A.PoklisJ. L.BogerD. L.et al. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther. 330, 902–910. 10.1124/jpet.109.155465
24
KinseyS. G.WiseL. E.RameshD.AbdullahR.SelleyD. E.CravattB. F.et al. (2013). Repeated low dose administration of the monoacylglycerol lipase inhibitor JZL184 retains CB1 receptor mediated antinociceptive and gastroprotective effects. J. Pharmacol. Exp. Ther. 345, 492–501. 10.1124/jpet.112.201426
25
LichtmanA. H.HawkinsE. G.GriffinG.CravattB. F. (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 302, 73–79. 10.1124/jpet.302.1.73
26
LongJ. Z.LiW.BookerL.BurstonJ. J.KinseyS. G.SchlosburgJ. E.et al. (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 5, 37–44. 10.1038/nchembio.129
27
LongJ. Z.NomuraD. K.VannR. E.WalentinyD. M.BookerL.JinX.et al. (2009b). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 20270–20275. 10.1073/pnas.0909411106
28
LynchM. E.CampbellF. (2011). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br. J. Clin. Pharmacol. 72, 735–744. 10.1111/j.1365-2125.2011.03970.x
29
MaioneS.BisognoT.De NovellisV.PalazzoE.CristinoL.ValentiM.et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 316, 969–982. 10.1124/jpet.105.093286
30
PertweeR. G. (2013). Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. Proc. Nutr. Soc. 73, 96–105. 10.1017/S0029665113003649
31
PetrosinoS.Di MarzoV. (2010). FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs11, 51–62.
32
PetrosinoS.PalazzoE.De NovellisV.BisognoT.RossiF.MaioneS.et al. (2007). Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology52, 415–422. 10.1016/j.neuropharm.2006.08.011
33
PiscitelliF.Di MarzoV. (2012). “Redundancy” of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem. Neurosci. 3, 356–363. 10.1021/cn300015x
34
RameshD.GamageT. F.VanuytselT.OwensR. A.AbdullahR. A.NiphakisM. J.et al. (2013). Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology38, 1039–1049. 10.1038/npp.2012.269
35
RussoR.LovermeJ.La RanaG.ComptonT. R.ParrottJ.DurantiA.et al. (2007). The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 322, 236–242. 10.1124/jpet.107.119941
36
SavinainenJ. R.SaarioS. M.LaitinenJ. T. (2012). The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol. (Oxf). 204, 267–276. 10.1111/j.1748-1716.2011.02280.x
37
SchlosburgJ. E.BlankmanJ. L.LongJ. Z.NomuraD. K.PanB.KinseyS. G.et al. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci. 13, 1113–1119. 10.1038/nn.2616
38
ScottD. A.WrightC. E.AngusJ. A. (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain109, 124–131. 10.1016/j.pain.2004.01.020
39
SmithP. B.ComptonD. R.WelchS. P.RazdanR. K.MechoulamR.MartinB. R. (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270, 219–227.
40
TorranceN.SmithB. H.BennettM. I.LeeA. J. (2006). The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J. Pain7, 281–289. 10.1016/j.jpain.2005.11.008
41
WalkerJ. M.HuangS. M.StrangmanN. M.TsouK.Sanudo-PenaM. C. (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. U.S.A. 96, 12198–12203. 10.1073/pnas.96.21.12198
Summary
Keywords
neuropathic pain, endocannabinoid, 2-arachidnoylglycerol, anandamide, FAAH, MAGL
Citation
Lau BK and Vaughan CW (2014) Targeting the endogenous cannabinoid system to treat neuropathic pain. Front. Pharmacol. 5:28. doi: 10.3389/fphar.2014.00028
Received
17 December 2013
Accepted
19 January 2014
Published
03 March 2014
Volume
5 - 2014
Edited by
Susan Hua, The University of Newcastle, Australia
Reviewed by
Matthias Klugmann, University of New South Wales, Australia; Lih-Chu Chiou, National Taiwan University, Taiwan
Copyright
© 2014 Lau and Vaughan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: benjamin.lau@sydney.edu.au
†These authors contributed equally to this work.
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.